Gene · 32
ACACB: acetyl-CoA carboxylase beta
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ACACB: acetyl-CoA carboxylase beta. Genes, record 32. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/32
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00763 | Acetyl-CoA carboxylase 2 | 2,458 | 11 | Ensembl, GeneID, HGNC |
Source UniProt
Patents45
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36008 | O00763 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36009 | O00763 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 6611 | O00763 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 948 | O00763 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6357 | O00763 | Espacenet |
| EP 4641203 A2 | 2025-10-29 | 198 | O00763 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 97 | O00763 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 98 | O00763 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5351 | O00763 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5351 | O00763 | Espacenet |
1 to 10 of 45
See all 45 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CLESACOSTAT | CHEMBL4567446 | Acetyl-CoA carboxylase inhibitor | INHIBITOR | ChEMBL |
| FIRSOCOSTAT | CHEMBL3407547 | Acetyl-CoA carboxylase negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | ChEMBL |
| OLUMACOSTAT GLASARETIL | CHEMBL3989947 | Acetyl-CoA carboxylase inhibitor | INHIBITOR | ChEMBL |
| PF-05175157 | CHEMBL3359265 | Acetyl-CoA carboxylase inhibitor | INHIBITOR | ChEMBL |
Trials19
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT04971785 | FIRSOCOSTAT | PHASE2 | 2025-11-26 | ClinicalTrials.gov |
| NCT04399538 | CLESACOSTAT | PHASE2 | 2023-04-13 | ClinicalTrials.gov |
| NCT04395950 | CLESACOSTAT | PHASE1 | ClinicalTrials.gov | |
| NCT04321031 | CLESACOSTAT | PHASE2 | 2025-03-21 | ClinicalTrials.gov |
| NCT03987074 | FIRSOCOSTAT | PHASE2 | 2021-07-15 | ClinicalTrials.gov |
| NCT03776175 | CLESACOSTAT | PHASE2 | 2020-09-23 | ClinicalTrials.gov |
| NCT03449446 | FIRSOCOSTAT | PHASE2 | 2020-12-03 | ClinicalTrials.gov |
| NCT03248882 | CLESACOSTAT | PHASE2 | 2020-03-10 | ClinicalTrials.gov |
| NCT03127956 | OLUMACOSTAT GLASARETIL | PHASE3 | 2019-02-05 | ClinicalTrials.gov |
| NCT03073486 | OLUMACOSTAT GLASARETIL | PHASE3 | 2019-02-05 | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsNIH grants914
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ACACB papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 8 | 2025 |
| P30DK063491 | Diabetes Research Center (DRC) | 4 | 2025 |
| R01CA090764 | PI3K/PTEN/Akt signaling and the genesis of cancer | 4 | 2025 |
| P01CA120964 | Molecular Pathogenesis of the Hamartoma Syndromes | 3 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 3 | 2025 |
| P30DK045735 | Yale Diabetes Research Center | 3 | 2025 |
| R01DK089312 | Mechanisms of lipid-induced bioenergetic stress in muscle | 3 | 2025 |
| R01DK117850 | Systems Genetics Dissection of Non-alcoholic Steatohepatitis | 3 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 2 | 2025 |
| P30CA014195 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
1 to 10 of 914Source NIH's project files
See all 914 nih grantsPapers1,556
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Oxeiptosis-Associated Molecular Subtyping and Immune Microenvironment Heterogeneity in Osteoarthritis. | Biomedicines | 2026 | 42792820 | PubTator, text mining | PubMed |
| Identification of functional genes and immune cell infiltration analysis in liposarcoma. | PLoS One | 2026 | 42726806 | PubTator, text mining | PubMed |
| An Integrated Analysis of Manganese Metabolism-Related Genes and Their Association With Biomarkers, Immune Infiltration, and Clinical Subtypes in Alzheimer's Disease. | Genes Brain Behav | 2026 | 42723412 | PubTator, text mining | PubMed |
| Interpretable Prediction of Ligand-Protein Binding without Protein Structural Information. | J Med Chem | 2026 | 42679162 | PubTator, text mining | PubMed |
| A Deep Learning Framework for the Discovery of Natural-Product Candidate Binders of Acetyl-CoA Carboxylase 2 (ACC2) with Potential Relevance to Cardiometabolic Lipid Metabolism. | Pharmaceuticals (Basel) | 2026 | 42515804 | PubTator, text mining | PubMed |
| Hyperhomocysteinemia promotes lipid deposition in skeletal muscle. | Front Neurol | 2026 | 42383022 | PubTator, text mining | PubMed |
| Exploring the Toxicological Impact and Mechanisms of DEHP Exposure on Prostate Cancer Through Network Toxicology and Machine Learning Algorithms. | Curr Med Chem | 2026 | 42304923 | PubTator, text mining | PubMed |
| Shared Plant-human Biology: Herbicide Effects and New Biomarkers Perspectives. | Curr Environ Health Rep | 2026 | 41925771 | PubTator, text mining | PubMed |
| Metabolomic Profiling of Tyrosine Kinase Inhibitor-Induced Endothelial Dysfunction and Cardiovascular Toxicity. | Metabolites | 2026 | 41893349 | PubTator, text mining | PubMed |
| Integrated transcriptomic and metabolomic analysis reveals potential candidate genes and regulatory pathways associated with egg weight in geese. | Poult Sci | 2026 | 41887172 | PubTator, text mining | PubMed |
1 to 10 of 1,556
See all 1,556 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/32
GET https://conductscience.org/api/genes/v1/32/patents?page=2